Interferon beta and glatiramer acetate modify over two decades the course of relapsing-remitting multiple sclerosis?
Keywords:
interferon beta, glatiramer, acetate, long-term treatment, multiple sclerosisAbstract
Introduction: Interferon beta (IFN beta) and glatiramer acetate (GA) improve over 2-3 years the course of relapsing-remitting multiple sclerosis (RRMS). It is uncertain whether these drugs mods be-neficially the disease over two decades.
Objective: To evaluate the long-term efficacy of IFN beta-lb, IFN beta-la s.c., IFN beta-la Lm. or GA in the treatment of RR MS.
Method: Six clinical parameters and three MRI indices were analyzed in 18 cohorts of RRMS pa-tients folloned up to 25 years. The parameters were compared prior and after IFN beta and GA treat-ment as well as in the treated and controls.
Results: Reduction of annual relapse rates by IFN beta and GA nos at the earlier stage of treatment more effective than at the later one. Progression ofdisability in the treated nos maker and slow:, espe-cially at the beginning, in comparison to the withdrawn from the therapy. The percentages of treated patients with 4th and 6th step of disability, but not with 7th at EDSS, nere significantly loner Time to the 6th step after 25-year IFN beta treatment nos prolonged. Time to the conversion of RRMS into sec-ondary progressive MS nos longer in some cohorts. Quality of life and cognition remained at higher level in the continuously treated with IFN beta-I b. Lesion volumes on 72-related brain MRI slightly less progressed in the treated over a long time with IFN beta-1 b than in the sporadically receiving this , drug.
Downloads
References
Goodin D., Frohman E., Garmany G. i wsp.: Metody terapii wpływające na przebieg stwardnienia rozsianego. Neurology 2002; 58:169–178.
Trojano M., Paolicelli D., Fujani A. i wsp.: The incidence rate of relapses and the risk of progression decrease with the duration of -interferon treatment exposure in MS. Multiple Sclerosis 2004; 10: suppl. 2, S238–S239.
Ford C., Johnson K., Brooks B. i wsp.: Sustained efficacy and tolerability of glatiramer acetate in RR MS patients, treated over 10 years. Multiple Sclerosis 2003; 9: suppl. 1, S120.
Veugelers B., Bhan V., Fisk J. i wsp.: Effectiveness of disease-modifying agents in MS: a longitudinal population-based comparison. Multiple Sclerosis 2005; 11: suppl. 1, S7–S8.
Langdon D., Ebers G., Traboulsee A. i wsp.: Interferon beta-1b 16-year long-term follow-up study: patient-reported outcomes. Multiple Sclerosis 2006; 12: suppl. 1, S188.
Ebers G., Traboulsee A., Li D. i wsp.: Final results from the interferon beta-1b 16-year long-term follow-up study. Multiple Sclerosis 2006; 12: suppl. 1, S189.
Ebers G., Goodin D., i A., i wsp.: The interferon beta-1b 16 year long-term follow-up study: predictive clinical and MRI markers. Multiple Sclerosis 2007; 13: suppl. 2, S50.
Compston A., Ebers G., Lassmann H. i wsp.: McAlpine’s multiple sclerosis. Churchill Livingstone. London 1998.
Cendrowski W. Stwardnienie rozsiane. PZWL. Warszawa 1993.
Csepany T., Mezei Z., Bereczki D. i wsp.: Long-term favourable response to immunomodulatory treatment in Hungarian patients suffering from MS. Multiple Sclerosis 2006; 12: suppl. 1, S185.
Haas J.: Long-term follow-up of immunomodulatory therapies: beta interferon and glatiramer acetate in early RRMS. Multiple Sclerosis 2006; 12: suppl. 1, S97.
Kappos L., Traboulsee A., Constaninescu C. i wsp.: Long-term subcutaneous interferon beta-1a therapy in patients with RRMS. Neurology 2006; 67:944–953.
Grupa badawcza CHAMPIONS: Interferon –1a podawany domięśniowo opóźnia rozwój pewnego klinicznie SR w ciągu 5 lat po pierwszym epizodzie demielinizacji. Neurology 2006; 66:678–684.
Ford C., Johnson K., Lisak R. i wsp.: A prospective open-label study of glatiramer acetate: over a decade of continuous use in MS. Multiple Sclerosis 2006; 12:309–320.
Miller A., Spada V., Beerkircher D. i wsp.: Long-term (up to 26 years), open-label, compassionate use study of glatiramer acetate in RRMS. Multiple Sclerosis 2005; 11: suppl. 1, S84.
Brown M., Skedgel C., Kirby S. i wsp.: DMD effectiveness in RRMS to decline with disability progression and years since onset. Multiple Sclerosis 2007; 13: suppl. 2, S45.
Oztekin N., Otekin M.: Early treatment with IFN-beta-1a (Avonex®) in patients with RRMS with mild disability: results of 6-year open-label follow-up. Multiple Sclerosis 2006; 12: suppl. 1, S194.
Barak Y., Kishner I., Taliansky A. i wsp.: Sustained effect of interferon beta-1a (Avonex) in MS: an observational long-term study. Multiple Sclerosis 2003; 9: suppl. 1, S33.
Cendrowski W.: Przebieg naturalny stwardnienia rozsianego w Polsce. Post. Hig. Med. Dośw. 1968; 22:655–681.
Kuhle J., Gugleta K., Hardmeier M. i wsp.: 10 year follow-up of the European Study of IFN-beta-1b (EUSPMS) in SP MS – interim report. Multiple Sclerosis 2006; 12: suppl. 1, S186.
Bornstein M., Miller A., Slagle S. i wsp.: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive MS. Neurology 1991; 41:533–539.
Weinshenker B., Bass B., Rice G. i wsp.: The natural history of multiple sclerosis. A geographically based study. 1. Clinical course and duration. Brain 1989; 12:133–146.
Pittock S., Mayr W., McClelland R. i wsp.: Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62:601–606.
Trojano M., Amato M., Pellegrini F. i wsp.: Effectiveness of IFN-beta in delaying the age at secondary progression and at assignment of irreversible disability milestones in MS. Multiple Sclerosis 2006; 12: suppl. 1, S187.
Rudick R., Cutter G., Bajer M. i wsp.: Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Multiple Sclerosis 2005; 11:626–634.
Carra A., Onaha P., Luetic G. i wsp.: Drops out analysis: 10 years follow-up in a cohort of RRMS patients in Argentina treated with interferons or glatiramer acetate. Multiple Sclerosis 2006; 12: suppl. 1, S84.
Confavreux Ch., Vukusic S., Adeleine P.: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an anamnesic process. Brain 2003; 126:770–783.
Debouverie M., LORSEP Group: Long-term efficiency of the disease-modifying treatment. Multiple Sclerosis 2007; 13: suppl. 2, S47.
Le Page E., Leray E., Laplaud D. i wsp.: Impact of disease-modifying therapies on long-term disability. Multiple Sclerosis 2005; 11: suppl. 1, S6.
Schlosshauer T., Steinbrecher A., von Hagen B. i wsp.: Secondary progression after initiating immunomodulatoring treatment in MS – a four-year follow-up. Multiple Sclerosis 2007; 13: suppl. 2, S47.
Matyas K., Bencsik K., Fütvesi J. i wsp.: Six-year follow-up RRMS patients with interferon-beta-1b treatment. Multiple Sclerosis 2004; 10: suppl. 2: S246–S247.
Paty D., Kappos L., Stam Moraga M. i wsp.: Long-term observational efficacy and safety follow-up of the PRISMS cohort. Multiple Sclerosis 2003; 9: suppl. 1, S138.
Confavreux Ch., Vukusic S.: Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606–616.
Langdon D., Reder A., Ebers D. i wsp.: EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long-term follow-up study. Multiple Sclerosis 2007; 13: suppl. 2, S268.
Li D., Ebers G., Traboulsee A. i wsp.: Interferon beta-1b 16-year long-term follow-up study: MRI outcomes. Multiple Sclerosis 2006; 12: suppl. 1, S188–S189.
Traboulsee A., Li D., Kappos L. i wsp.: Long-term clinical benefits from s.c. IFN beta-1a: a phased analysis of the PRISMS long-term follow-up study. Multiple Sclerosis 2006; 12: suppl. 1, S192.
Rovaris M., Comi G., Rocca M. i wsp.: Long-term follow-up with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI – monitored trial. Multiple Sclerosis 2007; 13:502–508.
O’Ferrall E., Metz L., Lavorato D. i wsp.: Discontinuation of disease-modifying therapy in RRMS is related to disability worsening and low baseline H-RQuoL: 5 year population-based study. Multiple Sclerosis 2005; 11: suppl. 1, S158-S159.
Comi G., O’Connor P., Antel J. i wsp.: Oral FTY720 (Fingolimod) in patients with RRMS. Neurology 2008; 70: suppl. 1: A120.
Coles A.: Alemtuzumab-compared with subcutaneous high-dose IFNB–1a in treatment-naive RRMS: primary efficacy outcomes of CamMS223 at 3 years. Neurology 2008; 70: suppl. 1, A228.
Le Page E., Comi G., Filippi M. i wsp.: Comparison of two therapeutic strategies in aggressive RRMS: mitoxantrone as induction for 6 month followed by IFN beta-1b versus IFN beta-1b. A 3-year randomized trial. Neurology 2008; 70: suppl. 1, A227.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2010 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
